Gloveless isolators don’t end interventions. Learn to assess intervention dependency in robotic aseptic filling and when glove ports are justified.
|Articles|March 2, 2014
Visit Our Booth
Visit Our Booth
Advertisement
Seamlessly progress from R&D to large scale production with Eppendorf’s DASGIP® and New Brunswick™ bioprocessing systems and software solutions. Single or parallel systems with working volumes from 35 mL to 2500 L. Eppendorf’s renowned expertise in plastics manufacturing produces high quality singleuse vessels from 100 mL up to 40 L working volumes.
Eppendorf, Hauppauge, NY
•
INTERPHEX Booth # 3738
Advertisement
Related to this article
Terry Katz, CEO and co-founder of ForgeStop Technology Corporation, explains how the company’s product is worth the investment by protecting products and patients.
The FDA has shelved its National Priority Voucher pilot, leaving sponsors that built CMC and launch-readiness plans around 1- to 2-month reviews facing uncertain timelines.
Regulators will test pharma companies against their own internal AI policies. Jaenisch, Muraru, and Pandey explain how to build defensible, inspection-ready AI practices.
Terry Katz, CEO and co-founder of ForgeStop Technology Corporation, explains how its connected technology can enhance anticounterfeiting and how data are handled within the product.
Celtic Renewables won the CPHI Award for Sustainable Pharma Excellence for its green chemicals used in pharmaceutical manufacturing. Bettina Brierley, chief commercial officer, talks about the adoption, capacity, and pricing of biosolvents.
Terry Katz, CEO and cofounder of ForgeStop Technology Corporation, explains the company’s CPHI Award-winning connected product technology and how it helps to combat drug counterfeiting.
FDA approved pimicotinib for TGCT based on a 56% response rate; its Project Orbis review signals tighter global launch planning for manufacturers.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Signs Point to FDA Shelving Priority Voucher Pilot, Stalling Fast-Track Drug Reviews
2
PharmTech’s Weekly Roundup—November 6, 2026: Impurities, Supply Resilience, and AI Accountability
3
Our Biggest Takeaways From AAPS PharmSci 360
4
PharmTech AI Pulse Check: Who's Accountable When a Vendor's AI Model Changes?
5